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Abstract: Trypanosoma evansi is a widely spread parasite that causes the debilitating disease “surra”
in several types of ungulates. This severely challenges livestock rearing and heavily weighs on
the socio-economic development in the affected areas, which include countries on five continents.
Active case finding requires a sensitive and specific diagnostic test. In this paper, we describe the
application of an unbiased immunization strategy to identify potential biomarkers for Nanobody
(Nb)-based detection of T. evansi infections. Alpaca immunization with soluble lysates from different
T. evansi strains followed by panning against T. evansi secretome resulted in the selection of a single
Nb (Nb11). By combining Nb11-mediated immuno-capturing with mass spectrometry, the T. evansi
target antigen was identified as the glycolytic enzyme enolase. Four additional anti-enolase binders
were subsequently generated by immunizing another alpaca with the recombinant target enzyme.
Together with Nb11, these binders were evaluated for their potential use in a heterologous sandwich
detection format. Three Nb pairs were identified as candidates for the further development of an
antigen-based assay for Nb-mediated diagnosis of T. evansi infection.
Keywords: Trypanosoma evansi; Nanobody; enolase; diagnosis; homologous and heterologous
detection assays
1. Introduction
Trypanosoma evansi is the most widely spread animal-infective trypanosome and causes a disease
known as “surra”, which affects both domestic livestock and wildlife (e.g., horses, cattle, camels,
buffaloes, pigs, and deer) [1–3]. The pathology is characterized by weight loss, drastic reductions of
draft power, diminished meat and milk production, and often leads to death of the infected animals.
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Hence, this has a significant socio-economic impact on the local cattle industry in the affected areas [4,5].
While the transmission of most salivarian trypanosomes depends on the tsetse fly, T. evansi has
extended its vector range to a number of hematophagous biting flies other than tsetse. This has allowed
T. evansi to spread beyond the “tsetse belt” and move out of Africa. Today, T. evansi is found in South
America, Africa, Asia, and even Oceania [6,7]. Occasionally, surra outbreaks threaten Europe, when
undiagnosed infected animals (camels, equids, and dogs) are brought into the continent and allow
the parasite to spread to new hosts [8]. Although rare, recent reports have described human T. evansi
infections, which could indicate that T. evansi may be an emerging human pathogen [9,10]. Compared
to tsetse-transmitted trypanosomosis, the containment of “surra” is challenging because of the lack of
vector specificity displayed by T. evansi. Due to these issues, disease control is largely based on the use
of trypanocides and preventive management methods [11]. In principle, drug treatment in livestock
should ideally be combined with a conclusive diagnosis of infection or cure. Therefore, establishing an
effective detection method for active infections is important in formulating appropriate strategies to
control T. evansi.
T. evansi strains are categorized into one of two groups depending on the presence (Type A)
or absence (Type B) of the gene encoding the RoTat1.2 variant surface glycoprotein (VSG) and/or
variation of their kinetoplast minicircle DNA [12–14]. The existing T. evansi diagnostic methods include
parasitological, nucleic acid-based, and immunological assays that allow detection of Type A and/or B
strains depending on the test. The parasitological techniques are based on direct parasite observation
using light microscopy but have the drawback of possessing a low sensitivity and only being effective
in the acute phase of the disease when the parasitemia tends to be relatively high. Nucleic acid-based
assays such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), or
recombinase polymerase amplification (RPA) consist of amplifying sequences specific to the T. evansi
genome and are effective to confirm active infections [15–18]. Unlike nucleic acid-based techniques,
immunological methods detect the presence of specific molecules at the protein level and several
immunoassays have been developed for T. evansi detection [19–21]. Immunoassays essentially fall
under one of two types; i.e., antibody-based and antigen-based assays. While the former employ
native or recombinant parasite antigens to capture circulating host antibodies, the latter make use of
antibodies or fragments thereof for the detection of circulating parasite antigens. Antigen-based assays
typically make use of an antibody pair consisting of so-called capturing and detecting antibodies.
These can either recognize the same epitope on the target antigen or can bind distinct epitopes, in which
case the assay is called homologous or heterologous, respectively. While homologous antigen-based
assays require the target antigen to be a multimer (or a monomer with repeating epitopes), this is not a
necessity for heterologous assays [22–24]. Importantly, in both formats the capturing and detection
antibodies should be able to outcompete infection-induced anti-parasite host antibodies [25], and must
neither cross-react with host anti-IgG autoantibodies [26]. These issues can be circumvented by the use
of camelid single-domain antibodies, otherwise known as Nanobodies (Nbs) [27–30].
Nbs are single-domain antibody fragments that correspond to the variable antigen-binding
domain (VHH) of camelid heavy-chain only antibodies (HCAbs) [31]. They represent the structural
and functional equivalent of the Fab fragment of conventional antibodies [32]. Despite the loss of the
variable light chain in HCAbs, VHHs retain the capacity to recognize and bind epitopes with large
surface areas due to the occurrence of longer antigen-binding loops (complementarity determining
regions, CDRs) compared to the those of conventional antibodies (especially true for CDRs 1 and 3) [33].
As a result, Nbs possess a convex paratope with extending CDRs that allow them to reach epitopes
that often cannot be easily accessed by conventional antibodies (such as clefts and cavities on the
antigen surface) [34,35]. The combination of their ability to recognize cryptic epitopes, their small
size (≈15 kDa for a Nb vs. ≈150 kDa for a conventional antibody), high thermostability and solubility,
ease of production in bacteria and the high-throughput identification of potent binders via display
technologies and biopanning procedures offers many advantages in the development of diagnostic
and therapeutic applications [31,36–38].
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In this paper, we describe the application of an unbiased immunization strategy to identify
potential biomarkers for Nb-based detection of a wide range of T. evansi strains (both Type A and B).
The approach consists of immunizing a camelid with a heterogeneous antigen mixture of unknown
compositions (e.g., parasite secretome or soluble lysate) to construct a Nb library which is then panned
against the same antigen mix. The identified Nbs are then used to determine the nature of their target
antigens via immunocapturing followed by mass spectrometry (MS). The approach is “unbiased”
given that Nb library construction is performed without prior knowledge of the target antigen(s)
recognized by the identified binders [24,39]. Here, we report the identification of a single anti-T. evansi
secretome Nb (Nb11) after immunizing an alpaca with soluble lysate preparations from different
T. evansi strains followed by panning and screening against the T. evansi secretome. Using subsequent
Nb11-mediated immunocapturing and MS, the Nb11 target was identified as the glycolytic enzyme
T. evansi enolase (TevENO). A combination of analytical gel filtration and ELISA shows that Nb11 can
be employed for the development of an antigen-based homologous immunoassay targeting TevENO.
Finally, immunization of a second alpaca with recombinantly produced TevENO yielded four additional
anti-TevENO Nbs, of which three can be used in conjunction with Nb11 to develop heterologous
TevENO sandwich detection assays.
2. Materials and Methods
2.1. Ethical Statement
All animal experiments were carried out according to the directive 2010/63/EU of the European
parliament for the protection of animals used for scientific purposes and approved by the Ethical
Committee for Animal Experiments of the Vrije Universiteit Brussel (clearance number 14-220-19 for
the alpaca immunization).
2.2. Secretome and Soluble Lysate Preparation
2.2.1. Secretome Preparation
Secretome from T. evansi strain STIB806 was kindly provided by Dr. Philippe Holzmuller (CIRAD
Montpellier, France). Secretome was prepared as previously described [40]. Briefly, isolated parasites
from infected rat blood were cultured at a density of 2 × 108 parasites mL−1 for 2 h at 37 ◦C in
secretion medium (Ringer Lactate, glucose 0.6%, KCl 0.4%, NaHCO3 0.125%, polymyxin B 5 mg mL−1,
L-glutamine 2 mM, MEM non-essential amino acids, pH 8.0). Parasite viability was determined by flow
cytometry after propidium iodide (PI) staining. Supernatant containing secretome was purified from
trypanosomes by centrifugation (1000× g for 10 min at 4 ◦C) and filtered using a 0.22 µm low-binding
protein filters. Secretome was aliquoted and stored at −80 ◦C after addition of the protease inhibitors
(30 µg mL−1 AEBSF; 1 µg mL−1 Leupeptin) until further use.
2.2.2. Soluble Lysate Preparation
Soluble lysates from different T. evansi strains (CAN86K, KETRI2479, RoTat 1.2, Merzouga I,
STIB816, and AnTaR3) were prepared from parasites isolated from infected mice. Briefly, the BALB/c
mice were infected with 10,000 parasites of each T. evansi stabilate intraperitoneally. The mice were
sacrificed at the parasitemia peak and heparinized blood was collected. Parasites were purified from
infected mice blood via DEAE-cellulose as described [41]. After washing three times in phosphate
saline glucose pH 8.0 (with CompleteTM protease inhibitor, Roche) through centrifugation, parasites
were counted under a light microscope and aliquoted at a density of 2 × 108 parasites mL−1. Total
lysates were prepared by performing three rounds of freezing and thawing followed by five sonication
rounds of 10 s each (Soniprep 150, SANYO, Osaka, Japan). After centrifugation at 20,817× g for 30 min,
the supernatant containing the soluble lysate was collected, aliquoted, and stored at −80 ◦C until
further use.
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2.3. Nb Library Construction and Phage Display
2.3.1. Construction of anti-T. Evansi Lysate and anti-TevENO Nb Libraries
The anti-T. evansi lysate Nb library was constructed by immunizing an alpaca with one of six
soluble lysate samples prepared from six different T. evansi strains in a sequential manner in order to
target conserved epitopes. Every week, 300 µg T. evansi soluble lysate prepared in a volume of 500 µL
was mixed with an equal volume of GERBU adjuvant (GERBU Biotechnik GmbH, Germany) prior to
injection. This process was repeated until the animal had been immunized with the soluble lysates
from each of the six selected strains over a course of 6 weeks (week 1: CAN86K, week 2: KETRI2479,
week 3: RoTat 1.2, week 4: Merzouga I, week 5: STIB816, week 6: AnTAR3). A total of 50 mL of blood
was collected from the alpaca 4 days after the last immunization. Two Nb libraries were constructed as
described previously [42].
The anti-TevENO Nb library was generated through the immunization of a second alpaca with
recombinantly produced TevENO on a weekly basis over a period of 6 weeks. Prior to injection, 100 µg
TevENO prepared in a volume of 500 µL was mixed with an equal volume of GERBU adjuvant. The
collection of lymphocytes from the immunized animal’s blood and subsequent library construction
were performed as described above.
2.3.2. Phage Display and Panning of the anti-T. Evansi Lysate Nb Library
The anti-T. evansi lysate Nb library (1 mL) was grown in 300 mL of 2×TY medium supplemented
with 100 µg mL−1 ampicillin and 2% glucose at 37 ◦C while shaking at 225 rpm, until OD600nm reached
0.6–0.8. After that, they were transfected with 1012 M13K07 helper phages (InvitrogenTM) for 30 min
at room temperature (RT). Transformants were harvested by centrifugation (1500× g for 10 min at
4 ◦C) and inoculated in 300 mL of fresh 2×TY medium supplemented with 100 µg mL−1 ampicillin,
70 µg mL−1 kanamycin, and 2% glucose. The culture was grown overnight at 37 ◦C with shaking
at 225 rpm. Finally, cultures were centrifuged (11,000× g for 30 min at 4 ◦C) and the supernatant
containing phage particles was collected and mixed with polyethylene glycol (PEG)/NaCl to precipitate
the phage particles and resuspended in a final volume of 1 mL. The concentration of phage particles
was determined by measuring the OD260nm (OD260nm of 1 = 3 × 1011 phages mL−1). A total of 1 × 1011
phages particles were used to pan against the T. evansi secretome (500 µg mL−1) coated overnight at
4 ◦C in the wells of a 96-well NUNC plate (Thermo scientific). The coated wells were blocked with
5% skimmed-milk, protein-free blocking buffer (Thermo scientific), and 0.1% casein in the sequential
panning rounds, to minimize the enrichment for binding to “blocking” reagents. Phage particles were
eluted with 100 µL of 100 mM triethylamine (pH 11.0) followed by neutralization with 100 µL 1 M
Tris-HCl (pH 8.2). Eluted phage particles were amplified by infecting fresh Escherichia coli TG1 cells
in the exponential phase. Panning of the Nb library was performed for three consecutive rounds on
T. evansi lysate Nb library.
Screening and selection of colonies carrying Nb fragments targeting the T. evansi secretome
were performed through an ELISA on periplasmic extracts (PE-ELISA). From the three rounds of
panning of the Nb library on T. evansi lysate, 190 individual colonies were randomly selected and
grown in 100 µL of 2×TY medium supplemented with 10% glycerol, 2% glucose, and 100 µg mL−1
ampicillin in 96-well round bottom culture plates. After overnight growing at 37 ◦C, cells were
inoculated in 1 mL of 2×TY medium supplemented with 2% glucose and 100 µg mL−1 ampicillin
in 96 deep-wells plates. After growing at 37 ◦C for 4–5 h with shaking at 500 rpm, the culture was
induced with 1 mM isopropyl β-D-1-thiogalactopyanoside (IPTG). After growing for another 4 h
at 37 ◦C with shaking at 500 rpm, cells were harvested by centrifugation for 20 min at 3220× g at
4 ◦C. The periplasmic extract containing Nbs was released through freeze-thaw cycles. In parallel,
NuncTM microtiter plates were coated with 500 µg mL−1 T. evansi secretome and uncoated wells were
used as a negative control for each colony. The next day, 100 µL of each periplasmic extract (PE) was
loaded in duplicate onto blocked wells and incubated for 1 h at room temperature. The PE-ELISA was
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detected by mouse anti-hemagglutinin-biotin antibody (anti-HA-biotin, Sigma) diluted in 1:4000 and
streptavidin-HRP conjugate antibody (Jackson ImmunoResearch laboratories) diluted in 1:4000. The
ELISA was developed by 3,3′,5,5′-tetramethylbenzine (TMB) substrate and stopped by 1:3 addition
of 1 M H2SO4. Based on the OD450nm, a true binder was considered when the signal ratio between
coated/uncoated wells was ≥2.
2.3.3. Phage Display and Panning of the anti-TevENO Nb Library
The anti-TevENO Nb library was panned against TevENO and T. evansi secretome in parallel.
Panning was performed as three consecutive rounds on T. evansi secretome at concentration of
500 µg mL−1 and four consecutive rounds on TevENO at different concentrations (10 µg mL−1 of 1st
Round, 5 µg mL−1 of 2nd Round, 2.5 µg mL−1 of 3rd Round, and 1 µg mL−1 of 4th Round, respectively).
Screening and selection of colonies carrying TevENO-targeting Nb fragments was only performed
on recombinant protein at concentration of 1 µg mL−1 via PE-ELISA. The approach was the same as
described above.
2.4. Production and Purification of Nbs
The pMECS plasmid containing the Nb gene was extracted from TG1 cells and transformed into
E. coli WK6 cells for Nb expression. Single colonies were pre-cultured in 5 mL Luria–Bertani (LB)
medium supplemented with 100 µg mL−1 ampicillin overnight at 37 ◦C. The next day, 1 mL of each
pre-culture was inoculated into a flask containing 330 mL of Terrific Broth (TB) medium supplemented
with 2% glucose, 2 mM MgCl2, and 100 µg mL−1 ampicillin. Cells were grown at 37 ◦C with shaking at
220 rpm until the OD600 nm reached 0.6–0.8 and gene expression induced by addition of 1 mM IPTG and
growing overnight at 28 ◦C with shaking at 220 rpm. Cells were harvested by centrifugation for 8 min
at 11,000× g at 4 ◦C. Pellets were lysed by osmotic shock and the PE was collected by centrifugation for
30 min at 11,000× g at 4 ◦C.
The PE extracts containing Nbs were incubated with His-Select Nickel resin (Sigma) for 1 h at RT
with shaking, then passed over a PD-10 column. Proteins were eluted with PBS (pH 7.5) containing
1 M of imidazole and further purified by size exclusion chromatography (SEC) on a Superdex 75 16/60
column (GE Healthcare) which was pre-equilibrated with PBS for at least one column volume. The Nbs
were finally eluted with PBS. Fractions containing the Nbs were pooled and stored at 4 ◦C for further
use. Each purification step was monitored by SDS-PAGE under reducing conditions and visualized by
Coomassie blue staining.
2.5. Immuno-Capturing and Antigen Identification by LC-MS
The immuno-capturing experiment was performed with His-tagged Nb11 on T. evansi secretome
to identify the target antigen recognized by Nb11. A total of 500 µg of T. evansi secretome and 25 µg
of Nb11-His-tagged were mixed in a final volume of 300 µL in PBS buffer and incubated at RT for
2 h. The Nb-antigen complex was isolated using the QuickPickTM IMAC kit (Bio-Nobile) following
the manufacturer’s instructions. Then, 20 µL samples from each step were collected individually
and analyzed on SDS-PAGE using 10% precast polyacrylamide gels (NuPAGE Bis-Tris gels, Thermo
scientific) under reducing conditions and visualized by Coomassie-blue staining. The band of interest
was excised from the SDS-PAGE gel and analyzed by LC-MS/MS as described [24].
2.6. Recombinant Production and Purification of TevENO
The gene encoding TevENO (TriTrypDB ID: TevSTIB805.10.3130) was codon optimized for
expression in E. coli. Gene synthesis and cloning were performed by GenScript. Briefly, the synthesized
gene was cloned into the pET21b vector (Novagen) using the NdeI and XhoI restriction sites. The
gene was designed such to equip TevENO with an N-terminal hexahistidine (His6) tag and a protease
cleavage site (TEV). The construct was transformed into chemocompetent E. coli BL21 (DE3) using
the CaCl2 method. After transformation, single colonies were pre-cultured overnight at 37 ◦C with
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aeration (250 rpm) in 10 mL TB medium supplemented with 0.2% glucose and 100 µg mL−1 ampicillin.
The next day, 1 mL of the pre-culture was employed to inoculate a flask containing 330 mL of TB
medium supplemented with 2% glucose, 2 mM MgCl2, and 100 µg mL−1 ampicillin. This main culture
was incubated at 37 ◦C with aeration (250 rpm) until OD600 nm reached 0.6–0.8. After the induction of
protein production by addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), the culture
was incubated at 30 ◦C for 6 h with aeration (250 rpm). Cells were harvested by centrifugation (30 min,
11,000× g, 10 ◦C; Avanti J-E Centrifuge, Beckman Coulter, J10 rotor). Bacterial pellets were resuspended
in 50 mL buffer A (50 mM sodium phosphate, 5 mM MgCl2, pH 7.0) per liter of bacterial culture. The
resulting 50 mL aliquots were flash-frozen using liquid nitrogen and stored at −20 ◦C until further use.
Prior to purification, aliquots were thawed on ice. Cells were lysed using a sonicator (Bioblock
Scientific Vibro Cell 75043; 90 sonication cycles of 5 s pulses at 20% amplitude with a 5 s pause
between each cycle) and the cell lysate was centrifuged (30 min, 30,966× g, 10 ◦C). The supernatant
was collected and filtered (0.45 µm). Protein purification was performed on an NGC chromatography
system (Bio-Rad) using immobilized ion metal affinity chromatography (IMAC) and SEC. A 5 mL
HisTrap HP nickel-sepharose column (GE Healthcare) was equilibrated with buffer A for at least
five column volumes. The sample was loaded on the column using the same buffer at a flow rate of
1 mL min−1. After loading, the column was further washed with five column volumes of the same
buffer. TevENO was then eluted by a linear gradient of buffer B (50 mM sodium phosphate, 5 mM
MgCl2, 1 M imidazole, pH 7.0) from 0% to 100% over 20 column volumes. The fractions containing
the target protein were pooled and concentrated to a final volume of 5 mL for the subsequent SEC
step on a Superdex 75 16/60 column (GE Healthcare), which was pre-equilibrated with at least one
column volume of buffer A. The sample was eluted at a flow rate of 1.5 mL min−1. Fractions containing
TevENO were pooled and stored at 4 ◦C. Each of the purification steps was monitored by SDS-PAGE
and Western blot under reducing conditions.
2.7. Thermal Stability of TevENO
Thermal shift assays were performed to optimize the purification and storage conditions of
TevENO. The experiments were performed on a CFX Connect Real-Time System Thermal Cycler
(Bio-Rad). Data were collected from 10 to 95 ◦C at a scan rate of 0.5 ◦C min−1. The fluorescence
signal was recorded every 0.5 ◦C. Experiments were performed in 96-well plates and the total sample
volume was 25 µL. To determine the optimal protein-dye ratio, a grid screen of various concentrations
of SYPRO orange dye (Life Technologies) (0×, 5×, 10×, 50×, 100×) and TevENO (0, 1, 5, 10, 25, and
50 µM) was carried out. After identification of a suitable condition (5× SYPRO orange dye and 10 µM
TevENO), buffer and additive screens were performed as previously described [43]. All experiments
were performed in triplicate.
2.8. ELISA
2.8.1. Indirect ELISA
Microtiter plates were coated with 1 µg mL−1 TevENO overnight at 4 ◦C and the excess of
non-coated protein was removed by washing the plate five times with PBS-Tween20 (0.01%) (PBST).
Residual protein binding sites were blocked by 300 µL blocking buffer (5% milk powder in PBS) and
incubated for 2 h at RT. After washing the plate with PBST for three times, 100 µL of each Nb was
loaded onto blocked wells at a concentration of 1 µg mL−1 and incubated for 1 h at RT. After five
washing steps with PBST, 100 µL of mouse anti-HA antibody (Eurogentec) diluted in 1:2000 in blocking
buffer was added to each well and the plate was incubated for 1 h at RT. The plate was subsequently
washed five times with PBST, incubated for 1 h at RT with 100 µL of goat anti-mouse HRP antibody
(Sigma) 1:4000 diluted blocking buffer, followed by five final washing steps with PBST. The ELISA
plates were developed by addition of 100 µL TMB substrate, incubated for 10 min at RT, and stopped
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by adding 50 µL 1 M H2SO4. The plates were read at OD450 nm with a VersaMax ELISA Microplate
Reader (Molecular Devices).
2.8.2. Sandwich ELISA
In the set-up of both homologous and heterologous sandwich ELISA assays, the capturing Nb
was His-tagged and the detection Nb was HA-tagged. For the homologous ELISA assay, the capturing
Nb was coated at varying concentration from 0 to 10 µg mL−1. After blocking with 5% skimmed-milk
protein diluted in PBS, 100 µL of 5 µg mL−1 TevENO in PBS was added to the blocked wells. The
detection Nb was added at varying concentration from 0 to 10 µg mL−1. For the heterologous ELISA
assay, the capturing Nb was coated at concentration of 1 µg mL−1, TevENO was diluted in PBS to a
final concentration of 1 µg mL−1, the detection Nb was added at concentration of 1 µg mL−1. The
following steps were the same as described in Section 2.8.1.
2.9. SDS-PAGE and Western Blot
SDS-PAGE analysis was performed on 12% Bis-Tris protein gels (Thermo Scientific). All samples
were mixed with 10× reducing agent (NuPAGE, Life technologies) and 4 × loading buffer (NuPAGE,
Life technologies) and boiled at 100 ◦C for 5 min. The electrophoresis was performed at 120 V for
90 min. The gel was visualized by staining with Coomassie blue for 30 min and destained overnight
with destaining solution (40% methanol, 10% acetic acid, and 50% distilled water). The PageRuler
Prestained Protein Ladder (ThermoFisher Scientific) was employed as a molecular mass marker.
The protein gel was transferred onto a HybondTM-C nitrocellulose membrane (Amersham
Bioscience) for 60 min at 110 V. The membrane was blocked with 5% skimmed-milk protein diluted
in PBS (blocking buffer) overnight at 4 ◦C. The membrane was washed with PBST for three times
and incubated for 1 h at RT with mouse anti-His antibody (Pierce) 1:2000 diluted in blocking buffer.
After five washing steps with PBST, the membrane was finally incubated with goat anti-mouse-HRP
antibody (Sigma) diluted at 1:4000 in blocking buffer for 1h at RT. After a final washing step (five times
with PBST), the membrane was developed with DAB Substrate (ThermoFisher) at RT until the bands of
interest became visible on membrane, after which the reaction was halted by washing the membrane
with water.
2.10. Circular Dichroism (CD) Spectroscopy
CD spectra were recorded on a J-175 spectropolarimeter (Jasco). Continuous scans were taken
using a 1 mm cuvette, a scan rate of 50 nm min−1, a band width of 1.0 nm, and a resolution of 0.5 nm.
Five accumulations were taken at 20 ◦C in buffer A at a protein concentration of 0.2 mg mL−1. The raw
CD data (ellipticity θ in mdeg) were normalized for protein concentration and number of residues,
yielding the mean residue ellipticity ([θ] in deg cm2 dmol−1) according to the following equation:
[θ] =
θ.MM
n.C.l
(1)
where molecular mass (Da), the number of amino acids, protein concentration in mg mL−1, and
pathlength of the cuvette (cm) are represented by MM, n, C, and l, respectively.
2.11. Enzyme Activity Assay
The TevENO activity was measured as previously described [44] with some modifications. Briefly,
the enolase activity was measured by coupling its reaction to PYK and LDH and by following the
decrease of NADH absorbance at 340 nm using a microplate reader (SpectraMax Plus 384, Molecular
devices). This enzyme kinetic assay was performed at 25 ◦C in a 100 µL reaction mixture containing 0.1
M triethanolamine/HCl, pH 7.6, 1.1 mM ADP (Sigma A2754), 0.42 mM NADH (Sigma N8129), 2 mM
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MgSO4, and 17 mM KCl. The auxiliary enzymes PYK and LDH mixture solution (Sigma P0294) were
used at 4 and 6 U mL−1. The substrate 2-PGA (Sigma 79480) was added as indicated.
The Michaelis constant (Km) of TevENO for 2-PGA was determined using the above-mentioned
reaction conditions, by varying the concentration of 2-PGA between 0 and 1 mM. Kinetic parameters
were calculated from Michaelis–Menten plots by curve-fitting of experimentally determined data using
SoftMax Pro7 Software (Molecular Devices).
V0 =
Vmax.[S]
(Km + [S])
(2)
where V0 = initial reaction rate (µmol min−1 mg−1), Vmax = enzyme maximum rate (µmol min−1 mg−1),
[S] = substrate concentration (µM), Km =Michaelis constant (µM) of the enzyme (TevENO). The raw
data (milliOD min−1) was transformed into specific enzymatic activity units (µmol min−1 mg−1) using
the follow equation:
Speci f ic activity (µmol min−1 mg−1) =
Absorbance decrease velocity
(
milli OD min−1
)
ext.
(
NADH 6220 M−1 cm−1
)
. path length (0.25cm). [enzyme]
(
mgmL−1
) (3)
2.12. Analytical SEC
The stoichiometry of TevENO-Nb11 complex was determined by analytical SEC using an ENrichTM
SEC 650 10 × 300 Column (Bio-Rad), pre-equilibrated in buffer A. Samples of 500 µL containing 500 µg
TevENO, 168.9 µg Nb11, or TevENO-Nb11 complex mixed at varying molar ratios (2:1, 2:2, 2:3, and
2:4), were injected onto the column and eluted at a flow rate of 1 mL min−1. The TevENO-Nb11
complexes were mixed and incubated for 1 h prior to their application on the column. The column was
calibrated with the BioRad molecular mass standard under the same conditions. The elution peaks of
all chromatograms were analyzed by SDS-PAGE as described above.
3. Results
3.1. An Unbiased Alpaca Immunization Strategy Using T. Evansi Soluble Lysates Yields a Single Nb able to
Recognize a T. Evansi Secretome Component
This work aimed at developing an antigen-based Nb-immunoassay for the universal detection of
both Types A and B T. evansi strains. Hence, an unbiased alpaca immunization strategy was designed
using multiple parasite isolates derived from various geographic regions covering three continents
(Figure 1). An alpaca was sequentially immunized with soluble lysate preparations from T. evansi
CAN86K (Type A), KETRI2479 (Type B), RoTat 1.2 (Type A), Merzouga I (Type A), STIB816 (Type A),
and AnTAR3 (Type A) in order to maximize the chances of identifying one (or more) target antigen(s)
common to all T. evansi strains. The resulting anti-T. evansi lysate Nb library was subsequently panned
against T. evansi STIB806 secretome, resulting in the identification of three potential binders (Figure 2a).
Sequence comparison of the CDR3 regions reveals that these Nbs represent three distinct families.
The binders were subsequently produced in E. coli and purified from a periplasmic extract via a
two-step purification protocol encompassing IMAC and SEC. This protocol yields highly pure Nbs,
which migrate with an expected molecular mass of ≈15 kDa (Figure 2b). Finally, the purified Nbs were
tested in an indirect ELISA setup, ensuring that the binders yield detectable ELISA signals against
the T. evansi STIB806 secretome, while not cross-reacting with mouse serum components (the T. evansi
STIB806 parasites used for secretome preparation were isolated from infected mouse blood). As a
result of these tests, Nb11 was retained for further assay development, as it fulfilled both requirements
(Figure 2c,d).
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3.2. Nb11 Targets T. Evansi Enolase
Next, a combination of immunocapturing and mass spectrometry (MS) analysis was employed to
determine the identity of the target antigen of the anti-T. evansi secretome binder Nb11. SDS-PAGE
analysis of a Nb11-mediated immunocapturing experiment on T. evansi STIB 806 secretome reveals
the presence of a single band with an apparent molecular mass of ≈55 kDa in the captured fraction
(Figure 3a), suggesting that Nb11 specifically recognizes a monomeric or a homo-oligomeric target
antigen. Subsequent MS analysis of the excised gel slab containing the protein band of interest
identifies the target antigen of Nb11 as the glycolytic enzyme T. evansi enolase (TevENO; TriTrypDB
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TevSTIB805.10.3130). Importantly, TevENO is 100% conserved among Types A and B T. evansi strains
and shows 100% amino acid sequence identity with T. brucei enolase (TbrENO).
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mediat immunocapturing experiment and sis. T. evansi secretome was allowed o in eract
with nickel beads loaded with His-tagged Nb11. After a washing step, the captured protein was eluted,
and all fractions were analyzed on a 12% SDS-PAGE developed with Coomassie blue stain. Lane M,
PageRuler Prestained Protein Ladder; Lane 1, eluted fraction; Lane 2, Nb11; Lane 3, wash fraction; Lane
4, secretome flow through; Lane 5, T. evansi secretome (starting material). Native TevENO and Nb11
migrate at ≈55 and ≈15 kDa and are indicated by purple and black arrows, respectively. The boxed
gel band was excised and sent for mass spectrometry (MS) analysis, which detected several peptides
(highlighted by purple boxes) covering up to 39.86% of the entire TevENO sequence. (b) Recombinant
production of TevENO in Escherichia coli. Samples of the bacterial culture were taken before induction
(Lane 1), 4 h aft r induction (Lane 2), 16 h after induction (Lane 3) and analyzed by SDS-PAGE (left)
and W stern blot (righ ). The band corr sponding to His-tag d T vENO is in icated by the purple arrow.
Lane M, PageRuler Prestai ed Protein La der. (c,d) Purification of recombinantly produced TevENO via
immobilized ion metal affinity chromatography (IMAC) (c) and size exclusion chromatography (SEC) (d).
The insets represent SDS-PAGE analyses of the purification procedure. Lane M, PageRuler Prestained
Protein Ladder; Lane 1, supernatant of the bacterial culture after sonication; Lane 2, pellet after sonication;
Lane 3, IMAC flow through; Lane 4, IMAC wash; Lanes ‘*’, various fractions collected during IMAC
elution and SEC. (e) Results of the TSA conducted with TevENO in an effort to improve its stability
during purification. The grey and purple traces represent the TevENO melting curves in the starting
(50 mM Tris, 200 mM KCl, 5 mM MgCl2, pH 8.0) and optimized (50 mM sodium phosphate, 5 mM
MgCl2, pH 7.0) buffers, respectively. (f) CD spectrum of TevENO, collected in the optimized purification
buffer, shows that the recombinantly obtained enzyme is properly folded. (g) Enzymatic activity of
recombinantly produced TevENO towards different concentration of its substrate 2-phosphoglycerate
(2-PGA). The inset shows a comparison of the kinetic parameters obtained for TevENO in this work and
those determined for TbrENO by Hannaert and co-workers [44]. (h) Titration curve of Nb11 on TevENO
via indirect ELISA. The black dashed line refers to the ELISA cut-off (without TevENO).
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To validate the interaction between Nb11 and TevENO, the latter was produced as a recombinant
protein in E. coli (Figure 3b) and purified using a two-step purification protocol consisting of IMAC
and SEC (Figure 3c,d). Given the 100% sequence identity between TevENO and TbrENO, purification
buffers were initially selected based on the published TbrENO purification protocol [44]. However, in
our case, we found that TevENO readily precipitates overnight in the SEC purification buffer (50 mM
Tris-HCl, 200 mM KCl, 5 mM MgCl2, pH 8.0). This indicates a sub-optimal TevENO stability under
the used conditions and renders this buffer unsuitable for long-term protein storage. Hence, thermal
shift assays (TSAs) were performed in an attempt to optimize the SEC buffer, such to improve protein
stability and reduce protein precipitation. As can be seen from Figure 3e, the TSA experiments led
to the identification of a buffer condition (50 mM sodium phosphate, 5 mM MgCl2, pH 7.0) in which
TevENO displays a higher thermal stability compared to the starting buffer (an increase in the apparent
melting temperature Tm from 46.93 to 53.96 ◦C). Importantly, TevENO no longer precipitates after
purification in this optimized SEC buffer, thereby facilitating long-term protein storage. In addition,
circular dichroism (CD) spectroscopy measurements and enzyme activity assays demonstrate that
the optimized purification conditions yield properly folded and active TevENO. The CD spectrum
of TevENO displays the typical features of a well-folded protein composed of both α-helices and
β-sheets (Figure 3f), which is consistent with the structural features of TbrENO [45]. The enzyme
kinetics experiments confirm that recombinant TevENO is enzymatically active and that the determined
kinetic parameters are consistent with values previously reported for TbrENO [44] (Figure 3g). The
above-mentioned protein production and purification protocol results in a yield of ≈50 mg pure,
functional TevENO per liter of bacterial culture.
Finally, an indirect ELISA confirms the specific interaction between Nb11 and TevENO (Figure 3h),
thereby opening up possibilities for the development of Nb11-based immunoassays targeting TevENO.
3.3. Nb11 Can Be Employed in a Homologous Sandwich Assay Targeting TevENO
Given the dimeric nature of TevENO [44,45], the possibility of employing Nb11 in a homologous
sandwich assay to detect TevENO was explored through a combination of analytical SEC and
ELISA experiments.
Analytical SEC was employed to determine the stoichiometry of the TevENO-Nb11 complex
through a titration. Here, Nb11 and TevENO were mixed in various molar ratios in terms of their
monomer equivalents (TevENO:Nb11 monomer ratios of 2:1, 2:2, 2:3, and 2:4) and the elution profiles
of the resulting complexes were compared to those collected for TevENO and Nb11 alone (Figure 4a–g).
In accordance with reports in the literature [44,45], TevENO behaves as a dimer in solution (Figure 4a,g).
Likewise, Nb11 elutes at a position expected for a monomeric single-domain antibody fragment
(Figure 4b,g). Mixing TevENO and Nb11 in 2:1 and 2:2 ratios (i.e., one and two copies of Nb11 per
TevENO dimer, respectively) leads to gradual shifts of the TevENO peak to the left, which indicates the
formation of gradually larger complexes. In combination with SDS-PAGE analyses of the collected
peak fractions, which clearly show that Nb11 and TevENO co-elute, these observations provide strong
support for the formation of distinct TevENO-Nb11 complexes at these molar ratios (Figure 4c,d,g).
Interestingly, at 2:3 and 2:4 ratios (i.e., three and four copies of Nb11 per TevENO dimer, respectively),
the position of the TevENO-Nb11 complex elution peak no longer shifts indicating that the size of the
complex no longer increases (Figure 4c,d,g). In addition, at these molar ratios, a Nb11 excess peak
appears which becomes larger with the addition of more Nb11. Altogether, the analytical SEC data
demonstrate that the stoichiometry of the TevENO-Nb11 complex is 2:2. In other words, the TevENO
dimer harbors two Nb11 binding sites, suggesting that this particular system would be suitable for the
development of a diagnostic test with a homologous set-up.
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The potential use of a Nb11-based homologous immunoassay for the detection of TevENO was
assessed through an ELISA experiment in which His- and HA-tagged versions of Nb11 (Nb11H and
Nb11HA) were employed as capturing and detecting agents, respectively. The ELISA was performed in
the format of a checkerboard titration in order to determine those concentrations of the Nb11 capturing
and detecting variants that yield the highest ELISA signal. The highest signal is observed when Nb11H
and Nb11HA are used at concentrations of 2.5 and 10 µg mL−1, respectively (Figure 4h).
3.4. Alpaca Immunization with Recombinant TevENO Yields Four Additional Nbs That Can Be Paired with
Nb11 in Heterologous Sandwich Assays Targeting TevENO
While homologous immunoassays have their merits, heterologous sandwich assays are more
appealing as they facilitate lateral flow assay (LFA) design, which is a potent format for the development
of a rapid diagnostic test (RDT). To enable the development of a heterologous immunoassay, a new
anti-TevENO Nb library was generated by immunizing an alpaca with recombinant TevENO in order to
obtain more TevENO-specific binders that can be used in combination with Nb11. A panning strategy
in which the library was screened against both recombinant TevENO and T. evansi secretome in parallel
resulted in the identification of four potential additional binders (Figure 5a). Based on a sequence
comparison of their CDR3 regions, these four Nbs belong to distinct families. These Nbs were produced
and purified (Figure 5b) and their binding specificity towards TevENO was confirmed in an indirect
ELISA (Figure 5c). A heterologous sandwich ELISA employing His-tagged Nb11 and HA-tagged
variants of the newly identified TevENO binders as capturing and detecting agents, respectively, shows
that three out of four (NbR1-10, NbR2-103, NbsR3-74) can be combined with Nb11 for successful
TevENO detection in this heterologous format (Figure 5d).
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2, and 3 regions of the anti-TevENO Nbs. (b) SDS-PAGE analysis of retrieved Nbs after purification.
Lane M, PageRuler Prestained Protein Ladder. (c) Indirect ELISA performed on recombinant TevENO
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4. Discussion
The ability to differentiate between ongoing and past infections represents an important difference
between antigen-based and antibody-based immunoassays. The latter are often burdened by the
presence of long-lasting antibodies that remain in circulation after parasite clearance, which makes
it cumbersome to distinguish current from past infections [46,47]. While this issue is non-existent
in antigen-based assays, this immunoassay type has its own requirements, especially with regards
to the target antigen or biomarker. The target antigen should be (i) stable in the host environment
and produced over the entire course of the infection, (ii) available at concentrations that allow for its
detection, (iii) specific for a given pathogen, and (iv) the capture and detection antibodies targeting
the antigen should be able to out-compete infection-induced host anti-pathogen antibodies [25,48–53].
Previously developed antigen-based immunoassays for T. evansi detection operated via an “unbiased”
methodology; i.e., raising antibodies against whole parasites or preparations of specific parasite
fractions without prior knowledge of the target antigen [19,54,55]. Typically, poly- or monoclonal
antibodies isolated from animals infected with T. evansi were employed in an ELISA format to probe
the sera of experimentally or naturally infected animals for the presence of T. evansi antigens. In these
studies, the nature of the target antigen(s) or biomarker(s) remained unknown, thereby potentially
hindering further assay optimization.
Here, we present the application of such an “unbiased” approach to the immunization of camelids
with the aim of generating Nbs that can be employed for (i) the development of parasite-specific
antigen-based immunoassays and (ii) the identification of the target antigen via Nb-mediated
immunocapturing followed by MS analysis. Our group has previously adopted this strategy for
the identification of novel biomarkers for the detection of active T. congolense infections [24,39]. The
immunization of alpacas with soluble proteome and secretome fractions from T. congolense yielded
highly specific Nbs targeting the glycolytic enzymes T. congolense aldolase (TcoALD) and T. congolense
pyruvate kinase (TcoPYK), respectively. Here, the sequential immunization of an alpaca with soluble
lysate preparations from different T. evansi strains has led to the identification of a single binder
(Nb11) targeting yet another glycolytic enzyme, T. evansi enolase (TevENO). Although these findings
were initially surprising, it has become increasingly clear that trypanosomal glycolytic enzymes are
enriched in the secreted fractions of many trypanosomes (including T. brucei brucei, T. b. gambiense,
T. congolense, and T. evansi) for reasons that remain enigmatic [56–59]. Interestingly, the potential
of glycolytic enzymes to serve as biomarkers for disease or infection is widely described in the
literature. Examples include Plasmodium vivax aldolase and P. falciparum glyceraldehyde-3-phosphate
dehydrogenase for malaria [60,61], tumor M2-pyruvate kinase for gastrointestinal cancer [62], human
α-enolase for Behcet’s disease and cancer [63], neuron-specific enolase to differentiate Creutzfeldt-Jakob
disease from other illnesses characterized by dementia [64], and enolase for both human and canine
leishmaniasis [65]. Hence, it would seem that TevENO has all the potential to serve as a biomarker for
the successful detection of active T. evansi infections.
While the use of TevENO as a candidate biomarker still requires thorough validation, the
work presented here lays important foundations for the further development of both homologous
and heterologous antigen-based immunoassays for the diagnosis of T. evansi infections. First, the
identification of TevENO as a target antigen has allowed its recombinant production and purification,
which, based on our experience with TcoALD and TcoPYK, will be important for assay optimization
and development [24,39]. Given that TevENO and TbrENO are 100% identical at the amino acid level,
the production and purification conditions described for TbrENO were initially applied. As reported
by Hannaert and colleagues [48], the His-tagged variant of the enzyme possesses the tendency to
aggregate overnight, which in turn precludes long-term protein storage and thus significantly hampers
assay optimization using recombinantly obtained TevENO. This issue was resolved in this work by
performing TSAs, which led to an adaptation of the composition of the TevENO purification buffers
described by Hannaert and co-workers [48]. Second, the characterization of the interaction between
TevENO and Nb11 provides insights with regards to the potential flaws and strengths of the possible
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assay set-ups. Analytical SEC experiments reveal a 2:2 stoichiometry for the Nb11-TevENO complex
(i.e., the TevENO dimer possesses two Nb11 binding sites), thereby advocating the development of a
Nb11-based homologous assay targeting TevENO. A homologous ELISA performed in a checkerboard
titration format to determine the optimal concentrations of capturing and detecting Nb11 shows that the
highest ELISA signal is obtained with concentrations of 2.5 and 10 µg mL−1, respectively. Interestingly,
both lowering and increasing the amount of capturing Nb11 appears to have a negative impact on the
ELISA signal. This is reminiscent of the observations made for the Nb474-based homologous sandwich
ELISA targeting TcoALD, which could be explained by “self-competition” or “washing out” effects [66].
Whether or not similar effects are at play for the Nb11-TevENO system remains to be investigated.
Third, the generation of additional anti-TevENO Nbs through alpaca immunization with recombinantly
obtained, functional TevENO enable the development of heterologous assays. Despite the utility
of a homologous immunoassay, heterologous sandwich assays are more easily translated from an
ELISA to a LFA format [39]. In turn, this facilitates the development of an RDT that can be employed
in resource-poor settings. In this respect, the NbR2-103/Nb11 pair seems especially interesting as
it generates the highest signal in a heterologous sandwich ELISA targeting recombinant TevENO.
Further experimentation will have to assess the performance of this Nb pair on naïve serum spiked
with TevENO, serum from experimentally infected animals (and thus containing native TevENO), and
field samples.
Finally, knowing the identity of the candidate biomarker generates insights on the potential
breadth of the above-mentioned Nb-based homologous and heterologous immunoassays. Given
that glycolytic enzymes are highly conserved among trypanosomatids, the possibility exists that the
Nb-based immunoassays targeting TevENO could be employed for the detection of trypanosomes
other than T. evansi. Indeed, this candidate biomarker would also enable diagnosis of infections with
T. brucei brucei, T. b. gambiense, T. b. rhodesiense, and T. equiperdum as TevENO, TbrENO, and TeqENO
are 100% identical at the amino acid level. Taken that all these pathogens have a specific geographic
distribution and host range, this means that a single screening tool could be employed in a one-health
approach in multiple locations. For the detection of both Human African Trypanosomosis and Atypical
Human Trypanosomosis outside the tsetse belt, the rapid diagnosis of trypanosomosis using an
ENO-based RTD could serve as a first line screening tool. In this case, parasitological confirmation
will always be a second step, before and individual treatment regimen is decided upon, after disease
stage determination. In contrast, when an ENO-based RTD would be used for animal trypanosomosis,
both the detection of T. brucei and T. evansi would result in the same treatment decision (individual
or herd-based), depending on the host animal or geographic location, not the trypanosome species.
Finally, an ENO-based positive test-score in horses would be the result of either a T. evansi or T.
equiperdum infection, which would be most likely result in a PCR-based follow-up of the individual
animal and a final veterinarian decision that would be instructed by the confirmation of a positive
trypanosomosis score, rather than the species determination of the actual infective agent.
5. Conclusions
In conclusion, the work presented in this paper identifies the glycolytic enzyme Enolase as a
candidate biomarker for the detection of trypanosome infections, and outines the possibility of using a
Nb-based immunoassay detecting TevENO as a diagnostic for active cases of trypanosomosis. The
data presented in this work provide a solid base for future validation of the test under field conditions.
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